Clinical trials
Prostatitis clinical trials
Below are recruiting prostatitis clinical trials, each written for real people, not researchers. We’re tracking 1,370 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05011383RecruitingPhase 2
High dose testosterone for prostate cancer with ATM, CDK12, or CHEK2 changes
This trial is testing whether high doses of testosterone can help treat advanced prostate cancer in men who have a specific genetic change (ATM, CDK12, or CHEK2). It is for patients whose cancer has stopped responding to current hormone therapies.
Aurora, ColoradoAges 18 years+ - NCT06942104RecruitingPhase 1
New imaging agent for advanced solid tumors
This trial tests a new imaging agent (18F-TRX) to see if it can better detect cancer spread in people with advanced solid tumors. It is designed for patients with specific cancers like high-grade brain tumors, advanced kidney cancer, or prostate cancer that has stopped responding to hormone therapy.
San Francisco, CaliforniaAges 18 years+ - NCT06764485RecruitingPhase 3
Comparing a new drug to standard therapy for advanced prostate cancer
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
Birmingham, AlabamaAges 18 years+ - NCT06168487RecruitingPhase 1
Telmisartan for stable prostate cancer
This trial tests the blood pressure medication telmisartan in men with prostate cancer who are already on a stable treatment and not needing an immediate change. The goal is to see if adding telmisartan can help control the cancer without extra side effects.
Lebanon, New HampshireAges 18 years+ - NCT07717268RecruitingPhase 2
Stereotactic Radiation Plus New Hormone Therapy for Prostate Cancer
This trial tests a targeted, high-dose radiation therapy (SBRT) plus a newer hormone drug (abiraterone or enzalutamide) for men whose prostate cancer has spread to a small number of spots (5 or fewer) and is no longer controlled by standard hormone therapy.
Zaragoza, AragonAges Any age - NCT07302451RecruitingPhase 2
Recovering erectile function after prostate cancer treatment
This trial tests a program to help men recover erectile function after prostate cancer treatment. It is for men with a specific type of prostate cancer that hasn't spread and who still have some erectile function.
NaplesAges 18 years+ - NCT07543757Recruiting
Blood test to help decide if prostate biopsy is needed
This study tests whether a new blood test called Proclarix can better predict which men actually have prostate cancer before they undergo a biopsy. If the test works well, it could help avoid unnecessary biopsies in the future.
Meridian, IdahoAges 40–75 - NCT06111781RecruitingPhase 2
Hormone Therapy and Radiation for Intermediate Risk Prostate Cancer
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
New Haven, ConnecticutAges 18 years+ - NCT07221825Recruiting
Radium-223 imaging study for men with prostate cancer
This study uses a special type of scan (quantitative SPECT) to measure how Radium-223 (Xofigo) works in your bones. It helps doctors better understand treatment for prostate cancer that has spread to the bones.
St Louis, MissouriAges 18 years+ - NCT07677254Recruiting
Real world study of prostate cancer treatments
This study looks at real-world data from men with metastatic castration-resistant prostate cancer (mCRPC) to understand what treatments they receive and how they do. It may help doctors learn more about which treatments work best.
East Hanover, New JerseyAges 18–115 - NCT07365423RecruitingPhase 2
Terbinafine for prostate cancer with rising PSA
This trial tests if the antifungal drug terbinafine can lower PSA levels in men whose prostate cancer has returned after standard treatments, but who are not yet ready for hormone therapy. It is for men with no distant spread seen on scans except possibly small lymph nodes.
BadenAges 18 years+ - NCT05958082Recruiting
Genetic testing education for Black men with prostate cancer
This study tests whether educational support helps Black men with high-risk prostate cancer complete genetic testing. It may make it easier to get genetic results that can guide care for you and your family.
Detroit, MichiganAges 18 years+ - NCT02971358Recruiting
Surgery for very high-risk or limited-spread prostate cancer
This trial looks at how safe and how well early prostate surgery works for men with newly diagnosed very high-risk prostate cancer or a limited number of metastases (cancer spread). It may help some people live longer and control the cancer, but eligibility is very specific.
ViennaAges 18–75 - NCT02971085Recruiting
Registry for prostate cancer on active surveillance
This study follows men with low-risk prostate cancer who choose active surveillance (watching closely instead of immediate treatment). It aims to better track which monitoring results stay reassuring over time, and when treatment might be needed.
SeoulAges 40–80 - NCT02997709Recruiting
Collecting prostate cancer body marker samples during treatment
This study collects and measures “biomarkers” (measurable signs in the body) from people with prostate cancer who are about to have surgery or radiation. The goal is to understand how prostate cancer behaves during treatment, which may help improve care in the future.
Miami, FloridaAges 30 years+ - NCT03079323RecruitingPhase 2
Radiation before or after surgery for prostate cancer spread to lymph nodes
This Phase 2 trial studies whether giving planned radiation to certain lymph node areas (para-aortic/“PART”) after surgery helps people whose prostate cancer has spread to lymph nodes (pN1). You would be screened after a specific lymph node surgery (ePLND) to see if you match their situation, then receive the trial’s radiation plan and follow-up.
LeuvenAges 18 years+ - NCT03237026Recruiting
Urine tests to predict outcomes in prostate cancer treatment
This study looks for urine markers (proteins and metabolites) that may help predict how prostate cancer patients respond to treatment and what their outcomes are. You may be asked to give a urine sample and allow use of your medical and treatment details for analysis (results are not shared with you).
TaipeiAges 30–100 - NCT03237702Recruiting
Study uses urine tests to understand prostate cancer
This study collects a small urine sample around the time of a prostate biopsy to look for chemical “signals” that may explain dangerous prostate cancer behavior. Your results are not shared with you, but the information may help researchers improve understanding and future care.
TaipeiAges 30–100 - NCT03294889RecruitingPhase 1/Phase 2
Single-dose SBRT for early prostate cancer
This trial tests a very short, one-time form of radiation (SBRT) to treat prostate cancer. It aims to see whether treating the prostate in one shot is safe and effective for carefully selected patients.
GenevaAges 18–85 - NCT03322891Recruiting
Helping African-American men understand prostate cancer care
This study tests an approach to improve health understanding for African-American patients with early-stage prostate cancer. It may help you communicate better with your care team and feel more confident managing your diagnosis and next steps.
Atlanta, GeorgiaAges 25–100 - NCT03344835Recruiting
Study database for adults with prostate cancer
This study sets up a database of people with prostate cancer so researchers can learn more about patterns and outcomes. It may help your care indirectly by improving how prostate cancer is studied in Hong Kong.
ShatinAges 18 years+ - NCT03408964Recruiting
Blood tests to predict treatment response in prostate cancer
This study checks whether certain blood markers can help predict how well people with prostate cancer will respond to therapy. It may help doctors choose the most effective treatment sooner by using information from your blood.
BellinzonaAges 18 years+ - NCT03492424Recruiting
Focal prostate cancer treatment study
This study looks at outcomes after “focal therapy,” a type of treatment that targets only part of the prostate, for people with newly diagnosed or returning prostate cancer. It may help researchers understand how well this targeted approach works and for whom.
New York, New YorkAges 18 years+ - NCT03594760RecruitingPhase 3
PSMA PET scan study using advanced computer imaging in prostate cancer
This Phase 3 study looks at how a PSMA PET scan can predict how prostate cancer will progress and how well treatment is working. If your doctor at CHUM orders this scan, you may be able to join to help refine better predictions for future patients.
Montreal, QuebecAges 18 years+
Hear when a new Prostatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostatitis?
- Yes. Clin2 currently lists 1,370 recruiting prostatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.